%0 Journal Article
%T PREDICTIVE CIRCULATING MARKERS FOR ANTHRACYCLINE CHEMOTHERAPY IN NON-METASTATIC BREAST CANCER
%A F. Curea
%A I. Botnariuc
%A O.G. Trifanescu
%A R.M. Anghel
%A S.M. Ilie
%A X.E. Bacinschi
%J Archive of "Acta Endocrinologica (Bucharest)".
%D 2017
%R 10.4183/aeb.2017.209
%X Anthracyclines are used in breast cancer both in early and advanced stages and their recommendation together with taxanes, either concurrently or sequentially, is debatable and individualized by phenotype. Circulating biomarkers have already been introduced in clinical practice for metastatic disease monitoring. We questioned whether it might be a role for these markers in neoadjuvant and adjuvant settings too and a general review was conducted
%K breast cancer
%K circulating biomarkers
%K anthracyclines
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516453/